Verastem, Inc. (VSTM)
| Market Cap | 479.62M |
| Revenue (ttm) | 30.91M |
| Net Income (ttm) | -209.47M |
| Shares Out | 87.84M |
| EPS (ttm) | -3.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,918,613 |
| Open | 5.53 |
| Previous Close | 5.54 |
| Day's Range | 5.37 - 5.73 |
| 52-Week Range | 4.01 - 11.25 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 16.50 (+202.2%) |
| Earnings Date | May 7, 2026 |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki... [Read more]
Financial Performance
In 2025, Verastem's revenue was $30.91 million, an increase of 209.14% compared to the previous year's $10.00 million. Losses were -$209.47 million, 60.3% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 202.20% from the latest price.
News
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced two-year ...
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant...
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple ...
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will p...
Verastem Earnings Call Transcript: Q4 2025
Delivered $30.9M net product revenue in 2025 post-FDA approval, with strong CO-PACK adoption and expanding prescriber base. Cash runway extends into 2027, with LGSOC franchise expected to be self-sustaining in H2 2026. Robust clinical pipeline and prudent capital management support future growth.
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial ...
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Verastem Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Sales growth and broad adoption continue for the lead therapy, with strong reimbursement and long patient duration. Key clinical trials are progressing, including a pivotal confirmatory study and promising results for the G12D inhibitor, with major data updates expected mid-year.
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced prelimina...
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that foll...
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic...
Verastem Transcript: Evercore ISI 8th Annual HealthCONx Conference
Avutometinib's launch in low-grade serous ovarian cancer is progressing well, with academic and community uptake growing as infrastructure matures. The G12D inhibitor shows best-in-class potential, with strong efficacy and tolerability, and pivotal trial readouts expected in 2027.
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...
Verastem Transcript: Jefferies London Healthcare Conference 2025
Strong commercial launch and clinical progress for avutometinib-defactinib in ovarian cancer, with expansion into pancreatic and lung cancer through a promising G12D inhibitor collaboration. Key regulatory, clinical, and commercial milestones are expected in the coming year.
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the prici...
Verastem Oncology Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it i...
Verastem Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Strong commercial momentum in LGSC is supported by targeted distribution and growing community uptake. RAMP 301 trial enrollment was slightly increased, with high confidence in both KRAS mutant and wild-type success. VS-7375 shows best-in-class efficacy, and U.S. trials are leveraging rapid Chinese data.
Verastem Oncology to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...
Verastem Earnings Call Transcript: Q3 2025
Q3 2025 saw $11.2M in net product revenue from a strong AVMAPKI FAKZYNJA CO-PACK launch, with broad adoption across academic and community settings. R&D and SG&A investments drove a $39.4M net loss, but cash reserves provide runway into 2026. Multiple clinical milestones are expected in 2026.
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business ...
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced encouragi...
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive,...
Verastem Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Accelerated FDA approval and strong early sales for the lead ovarian cancer therapy highlight commercial momentum, while robust clinical data in pancreatic and lung cancer support pipeline expansion. Financial runway extends into 2026, with strategic focus on partnerships and further clinical milestones.